Suzhou Basecare Medical Corporation Limited

Informe acción SEHK:2170

Capitalización de mercado: HK$908.1m

Suzhou Basecare Medical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bo Liang

Chief Executive Officer (CEO)

CN¥3.0m

Compensación total

Porcentaje del salario del CEO84.4%
Permanencia del CEO13.9yrs
Participación del CEOn/a
Permanencia media de la dirección6.2yrs
Promedio de permanencia en la Junta Directiva2.6yrs

Actualizaciones recientes de la dirección

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Recent updates

Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 18
Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Sep 27
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

May 09
Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Mar 22
Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Aug 01
Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

May 26
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Jul 20
Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bo Liang en comparación con los beneficios de Suzhou Basecare Medical?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-CN¥250m

Mar 31 2024n/an/a

-CN¥221m

Dec 31 2023CN¥3mCN¥3m

-CN¥192m

Sep 30 2023n/an/a

-CN¥176m

Jun 30 2023n/an/a

-CN¥160m

Mar 31 2023n/an/a

-CN¥146m

Dec 31 2022CN¥3mCN¥3m

-CN¥132m

Sep 30 2022n/an/a

-CN¥133m

Jun 30 2022n/an/a

-CN¥135m

Mar 31 2022n/an/a

-CN¥139m

Dec 31 2021CN¥4mCN¥3m

-CN¥144m

Sep 30 2021n/an/a

-CN¥119m

Jun 30 2021n/an/a

-CN¥106m

Mar 31 2021n/an/a

-CN¥490m

Dec 31 2020CN¥8mCN¥1m

-CN¥874m

Sep 30 2020n/an/a

-CN¥1b

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥822m

Dec 31 2019CN¥732kCN¥602k

-CN¥528m

Compensación vs. Mercado: La compensación total de Bo($USD420.86K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD233.47K).

Compensación vs. Ingresos: La compensación de Bo ha aumentado mientras la empresa no es rentable.


CEO

Bo Liang (43 yo)

13.9yrs

Permanencia

CN¥3,046,000

Compensación

Dr. Bo Liang serves as Executive Director and General Manager at Suzhou Basecare Medical Corporation Limited since December 14, 2010 and serves as its Chairman of the Board since December 14, 2015. Dr. Lia...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Bo Liang
Chairman of the Board & GM13.9yrsCN¥3.05msin datos
Lingyin Kong
CTO & Executive Director10.5yrsCN¥1.40msin datos
Ying Yang
Chief Quality Officer6.2yrsCN¥677.00ksin datos
Lejun Yin
CFO & Joint Company Secretary2yrssin datossin datos
Maoshe Rui
Chief Operating Officer7.4yrsCN¥306.00ksin datos
Junchao Jiang
Executive Directorless than a yearsin datossin datos
Ming Fai Chung
Joint Company Secretary2.3yrssin datossin datos

6.2yrs

Permanencia media

43yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2170 es experimentado (6.2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Bo Liang
Chairman of the Board & GM13.9yrsCN¥3.05msin datos
Lingyin Kong
CTO & Executive Director8.4yrsCN¥1.40msin datos
Junchao Jiang
Executive Directorless than a yearsin datossin datos
Xixiong Kang
Independent Non-Executive Director3.8yrsCN¥180.00ksin datos
Wenbo Xu
Non-Executive Director6yrssin datossin datos
Weipeng Wang
Non-Executive Director8.2yrssin datossin datos
Yi Lin
Supervisor4.3yrssin datossin datos
Siu Wing Lam
Independent Non-Executive Director1.3yrsCN¥84.00ksin datos
Shu Biu Yeung
Independent Non-executive Director1.3yrsCN¥70.00ksin datos
Yang Ling
Non-executive Director1.3yrssin datossin datos
Lijuan Shi
Chairwoman of the Supervisory Board1.3yrssin datossin datos
Qiuping Zong
Supervisor1.3yrssin datossin datos

2.6yrs

Permanencia media

43yo

Promedio de edad

Junta con experiencia: La junta directiva de 2170 no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.